KKKaveh Karimzad

Kaveh Karimzad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kaveh Karimzad has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Arrhythmias in Cancer Patients

    by Peter Kim, Jiyeon Cha, Abdulrazzak Zarifa, Mohammed Salih, Kaveh Karimzad

  • Open Access

    Atrial Cardiomyopathy and Atrial Fibrillation in Different Heart Failure Substrates

    by Bharat K Kantharia, Lingling Wu, Mohit M Hulsurkar, Kaveh Karimzad, Arti N Shah, Bharat Narasimhan, Xander Ht Wehrens, Dominik Linz, Jordi Heijman

    The incidences of AF and heart failure (HF) have been progressively increasing worldwide. These conditions exhibit a strong interdependence, with each exacerbating the other. HF is currently classified based on left ventricular ejection fraction (EF) as HF with reduced, mid-range or preserved EF (HFrEF, HFmrEF or HFpEF, respectively). Atrial cardiomyopathy, also known as atriopathy, involves structural, architectural, contractile, or electrophysiological alterations in the atria, driven by diverse mechanisms stemming from risk factors and comorbidities, including diabetes, hypertension, ischaemic and valvular heart diseases, hypertrophic and dilated cardiomyopathies, as well as various forms of HF. Emerging evidence also implicates infiltrative cardiomyopathies (e.g. cardiac amyloidosis), certain cancers, and chemotherapeutic agents in promoting both AF and HF. This review summarises key basic and translational science findings, along with their potential clinical applications, that connect shared pathophysiological substrates between HF and atrial cardiomyopathy.


  • Open Access

    Cardiac resynchronization therapy in patients with cancer: A single cancer center experience

    by Nicholas King, Meera Kapadia, Scott Schubert, Jerril Jacob, Juhee Song, Salil Kumar, Leslie Ynalvez, Bharat Kantharia, Anita Deswal, Kaveh Karimzad

  • Open Access

    Safety of Contemporary Radiation Therapy in Patients With Cardiac Implantable Electronic Devices: Implications for Clinical Practice

    by Kaveh Karimzad, Shalin Shah, Stephen F. Kry, Christopher Peeler, Julianne Pollard‐Larkin, Amit Koduri, Martin Chacon Portillo, Siddharth Chauhan, Atia Amatullah, Chase Miller, et al.

    Background: Radiation therapy (RT) can cause cardiac implantable electronic device (CIED) malfunction, primarily reset. Given changes in RT and CIED technologies, large observational studies examining malfunction of contemporary CIEDs during modern‐day RT are needed to guide clinical practice. Methods: Electronic medical records of all consecutive patients with CIEDs who underwent RT at a large tertiary cancer center between January 2015 and January 2022 were reviewed. All patients had CIED interrogation before and after completion of RT. Device‐related data and RT‐specific variables were collected. Statistical analyses were performed at the RT course level. Results: Over a period of 7 years, 677 patients (median age, 74 [interquartile range, 67. 8–79.2] years; 72% men) with CIEDs (498 [66%] pacemakers and 254 [34%] implantable cardioverter‐defibrillators) underwent 752 courses of RT (photon, 83.5%; proton, 10.5%; electron, 6%). Only 9 patients (1.3%) underwent CIED relocation before RT. Device malfunction was observed during 8 RT courses (1.1%), primarily soft reset with data loss. All device malfunctions were observed with neutron‐producing radiation (proton and photon >10 MV). CIED type (pacemaker or implantable cardioverter‐defibrillator), magnetic resonance imaging conditional or nonconditional system, and radiation site (thorax or nonthorax) did not show statistical differences between RT courses with reset versus no reset. No transient signal interference or oversensing due to RT was recognized by the CIED. Conclusions: CIED malfunction is a rare complication of contemporary RT, occurring primarily with neutron‐producing radiation, most of CIED malfunction cases are without serious clinical consequences. Transient signal interference and oversensing during RT does not appear to be a clinical concern in contemporary CIEDs.


  • Open Access

    Pacing Solutions for Immune Checkpoint Myocarditis and Associated Conduction Disorders

    by Nicolas L. Palaskas, Nicholas E. King, Keila C. Ostos-Mendoza, Andrea Ruiz-Jurado, Hyeon-Ju Ali, Efstratios Koutroumpakis, Anita Deswal, Cezar Iliescu, Jean-Bernard Durand, Kaveh Karimzad


  • Open Access

    Reclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease

    by Jin Wan Kim, Tariq J. Dayah, Awad Javaid, Dominique J. Monlezun, Dinu V. Balanescu, Teodora Donisan, Kaveh Karimzad, Abdul Hakeem, David L. Boone, Nicolas Palaskas, et al.

    Background and Objectives: Cancer and coronary artery disease (CAD) often coexist. Compared to quantitative coronary angiography (QCA), fractional flow reserve (FFR) has emerged as a more reliable method of identifying significant coronary stenoses. We aimed to assess the specific management, safety and outcomes of FFR-guided percutaneous coronary intervention (PCI) in cancer patients with stable CAD. Materials and Methods: FFR was used to assess cancer patients that underwent coronary angiography for stable CAD between September 2008 and May 2016, and were found to have ≥50% stenosis by QCA. Patients with lesions with an FFR > 0.75 received medical therapy alone, while those with FFR ≤ 0.75 were revascularized. Procedure-related complications, all-cause mortality, nonfatal myocardial infarction, or urgent revascularizations were analyzed. Results: Fifty-seven patients with stable CAD underwent FFR on 57 lesions. Out of 31 patients with ≥70% stenosis as measured by QCA, 14 (45.1%) had an FFR ≥ 0.75 and lesions were reclassified as moderate and did not receive PCI nor DAPT. Out of 26 patients with p = 0.03). Conclusions: Further studies are needed to define the optimal therapeutic approach for cancer patients with CAD. Using an FFR cut-off point of 0.75 to guide PCI translates into fewer interventions and can facilitate cancer care. There was an overall reduction in mortality in patients that received a stent, suggesting increased resilience to cancer therapy and progression.